Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flamigel RT
- Development stage
- Unknown
- Lead developer
- Flen Health
- Administration
- Topical
01
Overview
Flamigel RT is a hydro-active colloid gel developed by Flen Health specifically for the symptomatic treatment of radiotherapy-induced skin reactions, also known as radiation dermatitis. It is indicated for both low-grade reactions, such as redness, dryness, and itching (dry desquamation), and more severe reactions involving skin breakdown and blistering (moist desquamation). The gel works by forming a protective barrier against external contamination, maintaining a moist environment conducive to wound healing, and providing a cooling effect to alleviate discomfort. Classified as a medical device, it is applied topically three times daily starting from the initiation of radiotherapy treatment.
- Brand names
- Flamigel RT
Beyond the preview
Go deeper on Flamigel RT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Flamigel RT.